Litcius/Paper detail

Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial

François Bénard, Sara Harsini, Don Wilson, Katherine Zukotynski, Gad Abikhzer, Éric Turcotte, Mariève Cossette, Ur Metser, Jonathan Romsa, Montgomery Martin, Colin Mar, Fred Saad, Jean‐Paul Soucy, Bernhard J. Eigl, Peter C. Black, Andra Krauze, Steven Burrell, Alan Nichol, Jean‐Claude Tardif

2022The Lancet Oncology40 citationsDOI

Topics & Concepts

MedicineProstate cancerBreast cancerBone scintigraphyRadiologyBone metastasisCancerPopulationNuclear medicineProspective cohort studyOncologyInternal medicineEnvironmental healthMedical Imaging Techniques and ApplicationsProstate Cancer Treatment and ResearchBone health and treatments
Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial | Litcius